TY - JOUR T1 - 2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis JO - Reumatología Clínica (English Edition) T2 - AU - Sanmartí,Raimon AU - García-Rodríguez,Susana AU - Álvaro-Gracia,José María AU - Andreu,José Luis AU - Balsa,Alejandro AU - Cáliz,Rafael AU - Fernández-Nebro,Antonio AU - Ferraz-Amaro,Iván AU - Gómez-Reino,Juan Jesús AU - González-Álvaro,Isidoro AU - Martín-Mola,Emilio AU - Martínez-Taboada,Víctor Manuel AU - Ortiz,Ana M. AU - Tornero,Jesús AU - Marsal,Sara AU - Moreno-Muelas,José Vicente SN - 21735743 M3 - 10.1016/j.reumae.2015.05.002 DO - 10.1016/j.reumae.2015.05.002 UR - https://www.reumatologiaclinica.org/en-2014-update-consensus-statement-spanish-articulo-S2173574315000878 AB - ObjectiveTo establish recommendations for the management of patients with rheumatoid arthritis (RA) to serve as a reference for all health professionals involved in the care of these patients, and focusing on the role of available synthetic and biologic disease-modifying antirheumatic drugs (DMARDs). MethodsConsensual recommendations were agreed on by a panel of 14 experts selected by the Spanish Society of Rheumatology (SER). The available scientific evidence was collected by updating three systematic reviews (SR) used for the EULAR 2013 recommendations. A new SR was added to answer an additional question. The literature review of the scientific evidence was made by the SER reviewer's group. The level of evidence and the degree of recommendation was classified according to the Oxford Centre for Evidence-Based Medicine system. A Delphi panel was used to evaluate the level of agreement between panellists (strength of recommendation). ResultsThirteen recommendations for the management of adult RA were emitted. The therapeutic objective should be to treat patients in the early phases of the disease with the aim of achieving clinical remission, with methotrexate playing a central role in the therapeutic strategy of RA as the reference synthetic DMARD. Indications for biologic DMARDs were updated and the concept of the optimisation of biologicals was introduced. ConclusionsWe present the fifth update of the SER recommendations for the management of RA with synthetic and biologic DMARDs. ER -